Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) Stock Competitors & Peer Comparison
See RVMDW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RVMDW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RVMDW | $11.70 | -2.34% | 46.7B | -1.65 | -$7.21 | N/A |
| VRTX | $546.12 | -2.12% | 138.6B | 28.70 | $19.03 | N/A |
| REGN | $827.72 | -1.87% | 85.3B | 18.14 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,033.15 | -1.93% | 64.2B | 93.24 | $11.08 | N/A |
| MRNA | $145.55 | -2.23% | 57.8B | -17.86 | -$8.15 | N/A |
| RVMD | $210.02 | -0.40% | 44.6B | -23.81 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $358.26 | -1.22% | 38.3B | 63.04 | $5.68 | N/A |
| ALNY | $266.11 | +0.61% | 35.6B | 47.95 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
RVMDW vs VRTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while VRTX trades at $546.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas VRTX's P/E ratio is 28.70. In terms of profitability, RVMDW's ROE is -0.96%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, RVMDW is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
RVMDW vs REGN Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, REGN has a market cap of 85.3B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while REGN trades at $827.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas REGN's P/E ratio is 18.14. In terms of profitability, RVMDW's ROE is -0.96%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RVMDW is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
RVMDW vs VRNA Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RVMDW's ROE is -0.96%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, RVMDW is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
RVMDW vs ARGX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ARGX has a market cap of 64.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ARGX trades at $1,033.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ARGX's P/E ratio is 93.24. In terms of profitability, RVMDW's ROE is -0.96%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, RVMDW is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
RVMDW vs MRNA Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, MRNA has a market cap of 57.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while MRNA trades at $145.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas MRNA's P/E ratio is -17.86. In terms of profitability, RVMDW's ROE is -0.96%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, RVMDW is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check MRNA's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
RVMDW vs RVMD Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, RVMD has a market cap of 44.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while RVMD trades at $210.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas RVMD's P/E ratio is -23.81. In terms of profitability, RVMDW's ROE is -0.96%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, RVMDW is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
RVMDW vs SGEN Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RVMDW's ROE is -0.96%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RVMDW is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
RVMDW vs ONC Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ONC trades at $358.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ONC's P/E ratio is 63.04. In terms of profitability, RVMDW's ROE is -0.96%, compared to ONC's ROE of +0.14%. Regarding short-term risk, RVMDW is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
RVMDW vs ALNY Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ALNY has a market cap of 35.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ALNY trades at $266.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ALNY's P/E ratio is 47.95. In terms of profitability, RVMDW's ROE is -0.96%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, RVMDW is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
RVMDW vs INSM Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, INSM has a market cap of 27.4B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while INSM trades at $126.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas INSM's P/E ratio is -30.73. In terms of profitability, RVMDW's ROE is -0.96%, compared to INSM's ROE of -1.11%. Regarding short-term risk, RVMDW is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
RVMDW vs BNTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, BNTX has a market cap of 26.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while BNTX trades at $103.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas BNTX's P/E ratio is -13.46. In terms of profitability, RVMDW's ROE is -0.96%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, RVMDW is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
RVMDW vs INCY Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, INCY has a market cap of 25.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while INCY trades at $126.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas INCY's P/E ratio is 17.04. In terms of profitability, RVMDW's ROE is -0.96%, compared to INCY's ROE of +0.30%. Regarding short-term risk, RVMDW is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check INCY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
RVMDW vs ROIV Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ROIV trades at $34.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ROIV's P/E ratio is -33.23. In terms of profitability, RVMDW's ROE is -0.96%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, RVMDW is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check ROIV's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
RVMDW vs UTHR Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, UTHR has a market cap of 20.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while UTHR trades at $487.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas UTHR's P/E ratio is 17.45. In terms of profitability, RVMDW's ROE is -0.96%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, RVMDW is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
RVMDW vs GMAB Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, GMAB has a market cap of 20.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while GMAB trades at $33.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas GMAB's P/E ratio is 25.32. In terms of profitability, RVMDW's ROE is -0.96%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, RVMDW is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
RVMDW vs BGNE Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RVMDW's ROE is -0.96%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, RVMDW is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
RVMDW vs DNA-WT Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RVMDW's ROE is -0.96%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, RVMDW is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
RVMDW vs ASND Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ASND has a market cap of 16.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ASND trades at $270.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ASND's P/E ratio is -111.80. In terms of profitability, RVMDW's ROE is -0.96%, compared to ASND's ROE of +1.90%. Regarding short-term risk, RVMDW is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
RVMDW vs NBIX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while NBIX trades at $155.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas NBIX's P/E ratio is 22.49. In terms of profitability, RVMDW's ROE is -0.96%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, RVMDW is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
RVMDW vs JAZZ Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while JAZZ trades at $246.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas JAZZ's P/E ratio is 9.23. In terms of profitability, RVMDW's ROE is -0.96%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, RVMDW is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
RVMDW vs EXEL Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, EXEL has a market cap of 14.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while EXEL trades at $59.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas EXEL's P/E ratio is 16.86. In terms of profitability, RVMDW's ROE is -0.96%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, RVMDW is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check EXEL's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
RVMDW vs BBIO Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, BBIO has a market cap of 14.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while BBIO trades at $74.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas BBIO's P/E ratio is -20.01. In terms of profitability, RVMDW's ROE is -0.96%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, RVMDW is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
RVMDW vs SMMT Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while SMMT trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas SMMT's P/E ratio is -15.72. In terms of profitability, RVMDW's ROE is -0.96%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, RVMDW is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
RVMDW vs HALO Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, HALO has a market cap of 13.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while HALO trades at $110.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas HALO's P/E ratio is 20.56. In terms of profitability, RVMDW's ROE is -0.96%, compared to HALO's ROE of +1.81%. Regarding short-term risk, RVMDW is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
RVMDW vs BMRN Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while BMRN trades at $66.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas BMRN's P/E ratio is 31.99. In terms of profitability, RVMDW's ROE is -0.96%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, RVMDW is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
RVMDW vs KRTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RVMDW's ROE is -0.96%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RVMDW is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
RVMDW vs MDGL Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while MDGL trades at $541.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas MDGL's P/E ratio is -42.27. In terms of profitability, RVMDW's ROE is -0.96%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, RVMDW is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
RVMDW vs ARWR Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ARWR trades at $86.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ARWR's P/E ratio is -38.37. In terms of profitability, RVMDW's ROE is -0.96%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, RVMDW is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check ARWR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
RVMDW vs TECH Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while TECH trades at $72.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas TECH's P/E ratio is 37.34. In terms of profitability, RVMDW's ROE is -0.96%, compared to TECH's ROE of +0.09%. Regarding short-term risk, RVMDW is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
RVMDW vs RNAM Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RVMDW's ROE is -0.96%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RVMDW is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
RVMDW vs AXSM Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while AXSM trades at $206.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas AXSM's P/E ratio is -53.96. In terms of profitability, RVMDW's ROE is -0.96%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, RVMDW is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
RVMDW vs KRYS Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, KRYS has a market cap of 10.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while KRYS trades at $358.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas KRYS's P/E ratio is 44.89. In terms of profitability, RVMDW's ROE is -0.96%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RVMDW is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check KRYS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
RVMDW vs PRAX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, PRAX has a market cap of 9.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while PRAX trades at $351.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas PRAX's P/E ratio is -27.21. In terms of profitability, RVMDW's ROE is -0.96%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, RVMDW is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check PRAX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
RVMDW vs KYMR Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while KYMR trades at $117.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas KYMR's P/E ratio is -36.68. In terms of profitability, RVMDW's ROE is -0.96%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, RVMDW is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check KYMR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
RVMDW vs IONS Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, IONS has a market cap of 9.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while IONS trades at $58.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas IONS's P/E ratio is -33.77. In terms of profitability, RVMDW's ROE is -0.96%, compared to IONS's ROE of -1.11%. Regarding short-term risk, RVMDW is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check IONS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
RVMDW vs RXDX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RVMDW's ROE is -0.96%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RVMDW is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
RVMDW vs PTGX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, PTGX has a market cap of 9.4B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while PTGX trades at $145.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas PTGX's P/E ratio is 141.48. In terms of profitability, RVMDW's ROE is -0.96%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, RVMDW is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
RVMDW vs NUVL Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas NUVL's P/E ratio is -21.79. In terms of profitability, RVMDW's ROE is -0.96%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RVMDW is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check NUVL's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
RVMDW vs CYTK Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CYTK trades at $72.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CYTK's P/E ratio is -10.07. In terms of profitability, RVMDW's ROE is -0.96%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, RVMDW is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check CYTK's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
RVMDW vs CRNX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CRNX's P/E ratio is -16.86. In terms of profitability, RVMDW's ROE is -0.96%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RVMDW is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check CRNX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
RVMDW vs PCVX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while PCVX trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas PCVX's P/E ratio is -8.02. In terms of profitability, RVMDW's ROE is -0.96%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, RVMDW is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
RVMDW vs IMGN Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RVMDW's ROE is -0.96%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RVMDW is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
RVMDW vs TGTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while TGTX trades at $55.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas TGTX's P/E ratio is 20.28. In terms of profitability, RVMDW's ROE is -0.96%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, RVMDW is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check TGTX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
RVMDW vs IBRX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while IBRX trades at $8.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas IBRX's P/E ratio is -8.33. In terms of profitability, RVMDW's ROE is -0.96%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, RVMDW is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check IBRX's competition here
Abivax S.A. (NASDAQ: ABVX)
RVMDW vs ABVX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ABVX has a market cap of 8.4B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ABVX trades at $114.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ABVX's P/E ratio is -60.17. In terms of profitability, RVMDW's ROE is -0.96%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RVMDW is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
RVMDW vs BPMC Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RVMDW's ROE is -0.96%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, RVMDW is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
RVMDW vs APGE Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas APGE's P/E ratio is -31.19. In terms of profitability, RVMDW's ROE is -0.96%, compared to APGE's ROE of -0.30%. Regarding short-term risk, RVMDW is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
RVMDW vs CERE Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CERE's P/E ratio is -16.47. In terms of profitability, RVMDW's ROE is -0.96%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RVMDW is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
RVMDW vs IMVT Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while IMVT trades at $39.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas IMVT's P/E ratio is -13.92. In terms of profitability, RVMDW's ROE is -0.96%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, RVMDW is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
RVMDW vs TXG Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, TXG has a market cap of 8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while TXG trades at $62.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas TXG's P/E ratio is -106.19. In terms of profitability, RVMDW's ROE is -0.96%, compared to TXG's ROE of -0.09%. Regarding short-term risk, RVMDW is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
RVMDW vs TWST Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, TWST has a market cap of 7.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while TWST trades at $124.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas TWST's P/E ratio is -56.18. In terms of profitability, RVMDW's ROE is -0.96%, compared to TWST's ROE of -0.30%. Regarding short-term risk, RVMDW is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check TWST's competition here
Belite Bio, Inc (NASDAQ: BLTE)
RVMDW vs BLTE Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, BLTE has a market cap of 7.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while BLTE trades at $193.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas BLTE's P/E ratio is -103.53. In terms of profitability, RVMDW's ROE is -0.96%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, RVMDW is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check BLTE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
RVMDW vs SYRE Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, SYRE has a market cap of 7.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while SYRE trades at $88.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas SYRE's P/E ratio is -45.63. In terms of profitability, RVMDW's ROE is -0.96%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, RVMDW is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
RVMDW vs MTSR Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RVMDW's ROE is -0.96%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, RVMDW is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
RVMDW vs CAI Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CAI has a market cap of 7.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CAI trades at $25.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CAI's P/E ratio is 70.44. In terms of profitability, RVMDW's ROE is -0.96%, compared to CAI's ROE of +0.19%. Regarding short-term risk, RVMDW is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check CAI's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
RVMDW vs RYTM Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while RYTM trades at $102.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas RYTM's P/E ratio is -33.04. In terms of profitability, RVMDW's ROE is -0.96%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, RVMDW is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check RYTM's competition here
Merus N.V. (NASDAQ: MRUS)
RVMDW vs MRUS Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RVMDW's ROE is -0.96%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, RVMDW is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
RVMDW vs ACLX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RVMDW's ROE is -0.96%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RVMDW is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
RVMDW vs SRRK Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while SRRK trades at $55.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas SRRK's P/E ratio is -16.04. In terms of profitability, RVMDW's ROE is -0.96%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, RVMDW is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
RVMDW vs CGON Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CGON trades at $74.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CGON's P/E ratio is -27.76. In terms of profitability, RVMDW's ROE is -0.96%, compared to CGON's ROE of -0.25%. Regarding short-term risk, RVMDW is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
RVMDW vs RETA Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas RETA's P/E ratio is -66.29. In terms of profitability, RVMDW's ROE is -0.96%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RVMDW is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
RVMDW vs CNTA Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CNTA's P/E ratio is -22.63. In terms of profitability, RVMDW's ROE is -0.96%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RVMDW is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
RVMDW vs MIRM Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while MIRM trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas MIRM's P/E ratio is -6.93. In terms of profitability, RVMDW's ROE is -0.96%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, RVMDW is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check MIRM's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
RVMDW vs TVTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while TVTX trades at $65.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas TVTX's P/E ratio is -145.07. In terms of profitability, RVMDW's ROE is -0.96%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, RVMDW is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
RVMDW vs DNTH Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while DNTH trades at $108.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas DNTH's P/E ratio is -26.05. In terms of profitability, RVMDW's ROE is -0.96%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, RVMDW is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
RVMDW vs COGT Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while COGT trades at $34.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas COGT's P/E ratio is -16.47. In terms of profitability, RVMDW's ROE is -0.96%, compared to COGT's ROE of -0.73%. Regarding short-term risk, RVMDW is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
RVMDW vs PTCT Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while PTCT trades at $69.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas PTCT's P/E ratio is -29.74. In terms of profitability, RVMDW's ROE is -0.96%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, RVMDW is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check PTCT's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
RVMDW vs XENE Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, XENE has a market cap of 5.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while XENE trades at $59.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas XENE's P/E ratio is -12.71. In terms of profitability, RVMDW's ROE is -0.96%, compared to XENE's ROE of -0.44%. Regarding short-term risk, RVMDW is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
RVMDW vs LGND Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while LGND trades at $285.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas LGND's P/E ratio is 31.35. In terms of profitability, RVMDW's ROE is -0.96%, compared to LGND's ROE of +0.20%. Regarding short-term risk, RVMDW is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check LGND's competition here
Erasca, Inc. (NASDAQ: ERAS)
RVMDW vs ERAS Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ERAS trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ERAS's P/E ratio is -17.41. In terms of profitability, RVMDW's ROE is -0.96%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, RVMDW is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check ERAS's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
RVMDW vs CDTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RVMDW's ROE is -0.96%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, RVMDW is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check CDTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
RVMDW vs ORKA Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ORKA trades at $92.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ORKA's P/E ratio is -47.69. In terms of profitability, RVMDW's ROE is -0.96%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, RVMDW is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check ORKA's competition here
Abcam plc (NASDAQ: ABCM)
RVMDW vs ABCM Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RVMDW's ROE is -0.96%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RVMDW is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
RVMDW vs ISEE Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RVMDW's ROE is -0.96%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RVMDW is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
RVMDW vs CRSP Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CRSP trades at $55.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CRSP's P/E ratio is -11.72. In terms of profitability, RVMDW's ROE is -0.96%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, RVMDW is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check CRSP's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
RVMDW vs APLS Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas APLS's P/E ratio is 38.35. In terms of profitability, RVMDW's ROE is -0.96%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RVMDW is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
RVMDW vs DFTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while DFTX trades at $38.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas DFTX's P/E ratio is N/A. In terms of profitability, RVMDW's ROE is -0.96%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, RVMDW is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check DFTX's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
RVMDW vs ACAD Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ACAD trades at $28.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ACAD's P/E ratio is 12.62. In terms of profitability, RVMDW's ROE is -0.96%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, RVMDW is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check ACAD's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
RVMDW vs TERN Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas TERN's P/E ratio is -51.41. In terms of profitability, RVMDW's ROE is -0.96%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RVMDW is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check TERN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
RVMDW vs PBLS Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, PBLS has a market cap of 4.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while PBLS trades at $40.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas PBLS's P/E ratio is -45.93. In terms of profitability, RVMDW's ROE is -0.96%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, RVMDW is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check PBLS's competition here
Celcuity Inc. (NASDAQ: CELC)
RVMDW vs CELC Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CELC has a market cap of 4.7B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CELC trades at $95.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CELC's P/E ratio is -22.26. In terms of profitability, RVMDW's ROE is -0.96%, compared to CELC's ROE of -3.51%. Regarding short-term risk, RVMDW is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
RVMDW vs EWTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, EWTX has a market cap of 4.6B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while EWTX trades at $43.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas EWTX's P/E ratio is -23.28. In terms of profitability, RVMDW's ROE is -0.96%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, RVMDW is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check EWTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
RVMDW vs FOLD Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RVMDW's ROE is -0.96%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RVMDW is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check FOLD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
RVMDW vs DYN Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, DYN has a market cap of 4.5B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while DYN trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas DYN's P/E ratio is -7.54. In terms of profitability, RVMDW's ROE is -0.96%, compared to DYN's ROE of -0.64%. Regarding short-term risk, RVMDW is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check DYN's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
RVMDW vs AKRO Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RVMDW's ROE is -0.96%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, RVMDW is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
RVMDW vs ALPN Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RVMDW's ROE is -0.96%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RVMDW is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
RVMDW vs ELVN Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ELVN trades at $59.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ELVN's P/E ratio is -35.52. In terms of profitability, RVMDW's ROE is -0.96%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, RVMDW is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
RVMDW vs OPT Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas OPT's P/E ratio is -1.52. In terms of profitability, RVMDW's ROE is -0.96%, compared to OPT's ROE of +1.18%. Regarding short-term risk, RVMDW is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
RVMDW vs PRTC Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas PRTC's P/E ratio is -3.78. In terms of profitability, RVMDW's ROE is -0.96%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, RVMDW is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check PRTC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
RVMDW vs RLAY Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while RLAY trades at $19.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas RLAY's P/E ratio is -12.13. In terms of profitability, RVMDW's ROE is -0.96%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, RVMDW is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
RVMDW vs MRTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RVMDW's ROE is -0.96%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RVMDW is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check MRTX's competition here
Veradermics, Incorporated (NYSE: MANE)
RVMDW vs MANE Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while MANE trades at $98.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas MANE's P/E ratio is -31.34. In terms of profitability, RVMDW's ROE is -0.96%, compared to MANE's ROE of -0.29%. Regarding short-term risk, RVMDW is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check MANE's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
RVMDW vs VKTX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas VKTX's P/E ratio is -7.48. In terms of profitability, RVMDW's ROE is -0.96%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, RVMDW is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check VKTX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
RVMDW vs TLX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while TLX trades at $11.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas TLX's P/E ratio is 124.63. In terms of profitability, RVMDW's ROE is -0.96%, compared to TLX's ROE of +0.07%. Regarding short-term risk, RVMDW is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check TLX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
RVMDW vs LEGN Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while LEGN trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas LEGN's P/E ratio is -31.65. In terms of profitability, RVMDW's ROE is -0.96%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, RVMDW is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check LEGN's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
RVMDW vs IOVA Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, IOVA has a market cap of 3.9B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while IOVA trades at $8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas IOVA's P/E ratio is -12.04. In terms of profitability, RVMDW's ROE is -0.96%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, RVMDW is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check IOVA's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
RVMDW vs TARS Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, TARS has a market cap of 3.9B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while TARS trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas TARS's P/E ratio is -83.28. In terms of profitability, RVMDW's ROE is -0.96%, compared to TARS's ROE of -0.14%. Regarding short-term risk, RVMDW is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for RVMDW.Check TARS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
RVMDW vs ADPT Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while ADPT trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas ADPT's P/E ratio is -59.22. In terms of profitability, RVMDW's ROE is -0.96%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, RVMDW is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check ADPT's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
RVMDW vs CPRX Comparison September 2026
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RVMDW stands at 46.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, RVMDW is priced at $11.70 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RVMDW currently has a P/E ratio of -1.65, whereas CPRX's P/E ratio is 12.30. In terms of profitability, RVMDW's ROE is -0.96%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RVMDW is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for RVMDW.Check CPRX's competition here